Bioequivalence Studies
On this page
Direct answer
A bioequivalence (BE) study demonstrates that a test generic product reaches the systemic circulation at the same rate and extent as a reference innovator product, so the two can be declared interchangeable. Healthy volunteers receive test and reference in a randomised 2×2 crossover design with a washout of about five or more half-lives, and serial blood samples build concentration-time curves. The metrics are peak concentration (Cmax, rate), exposure (AUC0-t and AUC0-inf, extent) and descriptive Tmax; after log transformation, bioequivalence is declared when the 90 per cent confidence intervals of test-to-reference geometric mean ratios fall entirely within 80.00 to 125.00 per cent. In India these studies run under CDSCO oversight within the New Drugs and Clinical Trials Rules, 2019 framework, at approved centres under GCP, with biowaivers possible for certain BCS Class I drugs.
What you must remember
- Design logic: 2×2 crossover, usually fasting (plus a fed study where food matters); washout of at least about 5 half-lives; each subject is their own control, which is why crossover beats parallel.
- Metrics: Cmax for rate, AUC0-t and AUC0-inf for extent, Tmax descriptive; all key metrics log-transformed before analysis.
- The magic window: 90 per cent confidence intervals of the ratios must sit wholly within 80.00-125.00 per cent — the spine of the exam answer.
- Why 80-125 not 100: the band is symmetric on the log scale (log 1.25 equals −log 0.8), allowing ±0.223 log units either way.
- Sample size: driven by intra-subject variability and expected difference, commonly 24 to 60 subjects; highly variable drugs need replicate designs and widened limits.
- Indian regulation: CDSCO permission and ethics approval under the New Drugs and Clinical Trials Rules, 2019, at approved BA/BE facilities under GCP and GLP bioanalysis.
- Biowaiver logic: BCS Class I immediate-release products with rapid dissolution, established excipients and a wide therapeutic index may earn a waiver of in-vivo BE on dissolution grounds.
- Narrow therapeutic index caution: digoxin, phenytoin, ciclosporin and levothyroxine demand extra care in switching despite formal equivalence.
Reading a BE report line by line
Open a typical Indian BE report and check it against the decision rules. The design page: two sequences, two periods, a washout long relative to the drug's half-life, randomisation documented. The analytical validation: an HPLC-MS method validated for selectivity, linearity, precision and matrix stability, because a wobbly assay manufactures false differences. The plasma profiles of test and reference should visually superimpose, and the statistical table delivers the verdict — geometric mean ratios near 1.0, lower and upper 90 per cent confidence limits for AUC and Cmax inside 80-125. Watch failure modes rather than numbers: a truncated sampling schedule that misses the true Cmax, a washout too short so period effects contaminate treatment effects, a fed study on an uneven breakfast. When a product passes AUC but fails Cmax, the formulation's dissolution rate — not its extent — is the culprit, and the fix returns to pharmaceutics: particle size, disintegrant, or an excipient slowing release.
How examiners and practice frame it
Two misunderstandings recur. The first is treating 80-125 per cent as the difference between products; it is a confidence interval on the ratio of geometric means, and the whole interval — not the point estimate — must sit inside the band, which is why a bigger, more variable study can fail with a perfect-looking mean. The second is asking for "blood level studies" when the syllabus means metrics: the Cmax (rate) versus AUC (extent) pairing and the crossover's self-control logic carry the marks. In Indian practice, connect the chapter to the regulatory chain — CDSCO permission, ethics approval, approved centres, and the post-2019 tightening of GCP documentation after data-integrity concerns at some Indian CROs, one careful sentence in any generics essay. The biowaiver question earns full marks only with the complete condition set: BCS Class I, rapid dissolution in multiple pH media, essentially the same excipients, and a wide therapeutic index.
Frequently asked questions
What design is standard for an oral bioequivalence study?
A randomised two-treatment, two-period, two-sequence crossover in healthy volunteers with an adequate washout (about 5 half-lives or more), so each subject receives both products as their own control.
What acceptance criterion defines bioequivalence?
The 90 per cent confidence interval of the log-transformed test-to-reference ratios for Cmax and AUC must fall entirely within 80.00 to 125.00 per cent.
Why is the bioequivalence window 80-125 rather than 80-120?
The bounds are symmetric on the logarithmic scale — 125 per cent up mirrors 80 per cent down (log 1.25 = −log 0.8) — so the arithmetic band merely looks asymmetric.
Which drugs may be granted a biowaiver of in-vivo studies?
BCS Class I drugs (highly soluble, highly permeable) in immediate-release forms with rapid dissolution in multiple pH media, established excipients and a wide margin of safety.
How do Cmax and AUC differ as bioequivalence metrics?
Cmax reflects the rate of absorption and peak exposure, while AUC reflects total extent of systemic exposure — a product can match extent yet fail on rate, implicating its dissolution profile.